Publications by authors named "David Hollenback"

Claim this Profile
D
Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease.
David Hollenback, Eva Hambruch, Gero Fink, Manfred Birkel, Andreas Schulz

J Pharmacol Exp Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the mouse model of sclerosing cholangitis.
Claudia D Fuchs, Natalie Sroda, Hubert Scharnagl, Ruchi Gupta, Wesley Minto, David Hollenback

JHEP Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Archana Vijayakumar, Ayse Okesli-Armlovich, Ting Wang, Isabel Olson, Minji Seung, David Hollenback

Hepatol Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Jamie Bates, Archana Vijayakumar, Sarani Ghoshal, Bruno Marchand, Saili Yi, David Hollenback

J Hepatol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Kathleen Keegan, Cong Li, Zhihong Li, Ji Ma, Mark Ragains, David Hollenback

Mol Cancer Ther· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Energy balance in congenital generalized lipodystrophy type I.
Sasha Taleban, Heather T Carew, Helén L Dichek, Samir S Deeb, David Hollenback

Metabolism· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
Paul La Rosée, Taiping Jia, Shadmer Demehri, Nicolai Härtel, Peter de Vries, David Hollenback

Clin Cancer Res· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia.
Michael G Douvas, Karen N Hogan, YanShan Ji, David Hollenback, Lynn Bonham

Leuk Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substrate specificity of lysophosphatidic acid acyltransferase beta -- evidence from membrane and whole cell assays.
David Hollenback, Lynn Bonham, Laura Law, Eddie Rossnagle, Lisa Romero

J Lipid Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diamino-C,N-diarylpyridine positional isomers as inhibitors of lysophosphatidic acid acyltransferase-beta.
Feng Hong, David Hollenback, Jack W Singer, Peter Klein

Bioorg Med Chem Lett· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
John M Pagel, Christian Laugen, Lynn Bonham, Robert C Hackman, David M Hockenbery, David Hollenback

Clin Cancer Res· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis.
Lynn Bonham, David W Leung, Thayer White, David Hollenback, Peter Klein

Expert Opin Ther Targets· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells.
Michael Coon, Alexey Ball, Jeannine Pound, Sophe Ap, David Hollenback

Mol Cancer Ther· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis